A Prospective, Vehicle Controlled, Double Blinded, Multicenter, Randomized, Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2017
At a glance
- Drugs B 244 (Primary)
- Indications Hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors AOBiome
- 27 Jun 2017 Status changed from active, no longer recruiting to completed.
- 13 Apr 2017 According to an AOBiome media release, the company expects to complete this trial in the second half of 2017.
- 17 Mar 2017 Status changed from recruiting to active, no longer recruiting.